Welcome to our dedicated page for KalVista Pharmaceuticals news (Ticker: KALV), a resource for investors and traders seeking the latest updates and insights on KalVista Pharmaceuticals stock.
KalVista Pharmaceuticals, Inc. (KALV) is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of small molecule protease inhibitors. The company's mission is to bring innovative treatments to patients suffering from a range of diseases, with a strong focus on hereditary angioedema (HAE) and diabetic macular edema (DME).
KalVista's core business revolves around developing small molecule plasma kallikrein inhibitors. Their product portfolio includes:
- Hereditary Angioedema (HAE) inhibitors: These inhibitors are designed to prevent and treat the debilitating attacks associated with HAE, a disorder characterized by severe swelling in various body parts.
- Diabetic Macular Edema (DME) inhibitors: These inhibitors target plasma kallikrein, which is implicated in the retinal vascular permeability that leads to DME, a common complication of diabetes that can cause vision loss.
The company operates primarily in the United States and has made significant strides in its research and development efforts. Recent achievements include successful clinical trials, strategic partnerships, and securing funding to advance their pipeline projects.
KalVista maintains a robust financial condition, supported by several rounds of funding and strategic investments. The company prioritizes transparency and regularly updates stakeholders on its progress through press releases and public disclosures.
Investors looking to keep abreast of the latest developments and financial performance of KalVista Pharmaceuticals can find comprehensive updates and reports on their official website and through stock market platforms like StockTitan.
Rhea-AI Summary
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) announces positive results from the Phase 3 KONFIDENT clinical trial for sebetralstat, a potential first oral on-demand therapy for hereditary angioedema. The trial met all endpoints, demonstrating a favorable safety profile. The company closed a successful underwritten offering, appointing Benjamin L. Palleiko as the new CEO. Financially, the company reported no revenue for the quarter, with increased R&D and G&A expenses leading to a net loss of $29.0 million. Cash position decreased to $75.6 million as of January 31, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.77%
Tags
-
Rhea-AI Summary
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) announces the acceptance of multiple abstracts at the 2024 HAEi Regional Conference, showcasing research on hereditary angioedema treatment patterns and patient perceptions. The company is a Silver-level sponsor of the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.53%
Tags
-
News
Rhea-AI Summary
KalVista Pharmaceuticals appoints Benjamin L. Palleiko as CEO to lead the transition to a commercial entity with sebetralstat for HAE. NDA filing on track for H1 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.61%
Tags
News
Rhea-AI Summary
KalVista Pharmaceuticals, Inc. (KALV) will participate in a fireside chat at the Leerink Partners 2024 Global Biopharma Conference on March 12th, 2024. The company focuses on oral protease inhibitors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.86%
Tags
-
Rhea-AI Summary
KalVista Pharmaceuticals, Inc. granted seven newly-hired employees inducement options to purchase 43,000 shares of KalVista common stock. The options have an exercise price of $14.14 per share and vest over a four-year period, subject to continued service.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.78%
Tags
-
Rhea-AI Summary
KalVista Pharmaceuticals presented real-world data revealing treatment delays, suboptimal outcomes, and anxiety linked to injectable treatments for Hereditary Angioedema (HAE) patients at AAAAI 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.79%
Tags
Rhea-AI Summary
KalVista Pharmaceuticals, Inc. presents positive data on phase 3 KONFIDENT trial for sebetralstat at AAAAI 2024, showcasing high efficacy with one dose, safety, and flexibility in dosing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.82%
Tags
-
Rhea-AI Summary
KalVista Pharmaceuticals, Inc. announces entry into UK Innovative Licensing and Access Pathway (ILAP) for sebetralstat, a plasma kallikrein inhibitor for hereditary angioedema. Late-breaking phase 3 data to be presented at 2024 AAAAI Annual Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.13%
Tags
-
Rhea-AI Summary
KalVista Pharmaceuticals, Inc. announces late-breaking phase 3 data for the KONFIDENT trial at the 2024 AAAAI Annual Meeting. The company presents multiple abstracts on Hereditary Angioedema attacks and treatment patterns.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.68%
Tags
Rhea-AI Summary
KalVista Pharmaceuticals, Inc. announces the pricing of its underwritten public offering, expecting gross proceeds of $160.1 million. The offering includes common stock and pre-funded warrants, with an option for additional shares. The pre-funded warrants are immediately exercisable.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.5%
Tags
FAQ
What is the current stock price of KalVista Pharmaceuticals (KALV)?
The current stock price of KalVista Pharmaceuticals (KALV) is $8.76 as of January 7, 2025.
What is the market cap of KalVista Pharmaceuticals (KALV)?
The market cap of KalVista Pharmaceuticals (KALV) is approximately 433.4M.
What does KalVista Pharmaceuticals specialize in?
KalVista Pharmaceuticals specializes in the discovery, development, and commercialization of small molecule protease inhibitors.
What diseases does KalVista target with its products?
KalVista targets hereditary angioedema (HAE) and diabetic macular edema (DME) with its products.
What is a plasma kallikrein inhibitor?
A plasma kallikrein inhibitor is a type of medication that blocks the action of plasma kallikrein, which plays a role in conditions like HAE and DME.
Where does KalVista Pharmaceuticals operate?
KalVista Pharmaceuticals operates primarily in the United States.
How can investors stay updated on KalVista's progress?
Investors can stay updated through KalVista's official website and stock market platforms like StockTitan.
Has KalVista formed any strategic partnerships?
Yes, KalVista has formed several strategic partnerships to advance its research and development efforts.
What are KalVista's recent achievements?
Recent achievements include successful clinical trials, securing funding, and strategic partnerships.
What is hereditary angioedema (HAE)?
Hereditary angioedema (HAE) is a disorder characterized by severe swelling in various parts of the body.
What is diabetic macular edema (DME)?
Diabetic macular edema (DME) is a complication of diabetes that affects the retina and can lead to vision loss.
What financial condition is KalVista in?
KalVista maintains a robust financial condition, supported by several rounds of funding and strategic investments.
KalVista Pharmaceuticals, Inc.
Nasdaq:KALV
KALV Rankings
KALV Stock Data
433.38M
43.78M
1.36%
110.29%
14.98%
Biotechnology
Pharmaceutical Preparations
United States of America
CAMBRIDGE